A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Capivasertib (Primary) ; Abemaciclib; Fulvestrant; Palbociclib; Ribociclib
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CAPItello-292
- Sponsors AstraZeneca
- 09 May 2024 The protocol has been amended to change in time frame for primary endpoint of Progression Free Survival (PFS).
- 09 Feb 2024 Planned number of patients changed from 850 to 628, as per Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium
- 09 Dec 2023 Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium